The definitive guide to gene editing.
Menu
Home Learn News Ask the Atlas
Explore Technologies Diseases Treatments Clinical Trials Companies Scientists Genes Research Institutions
Beyond medicine Agriculture Ethics Investing World map
Learn & Tools Start here Glossary A–Z Compare technologies Timeline Lists & Rankings AI Agents ★ Saved API
About About us Methodology Data Sources Editorial Policy Contact Disclaimers

🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.

⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.

Interface language
Light mode

The map of the gene-editing revolution

The CRISPR Atlas

Explore the technologies, treatments, diseases, scientists, companies, clinical trials and discoveries shaping the future of genetic medicine.

17 technologies 19 diseases 15 treatments 14 clinical trials 17 companies 19 genes Educational reference · research only · never medical advice
You are in Guided View. Terms are explained as you go, and every page opens with a plain-language summary before the technical detail. Switch back to Expert View from the menu at any time.

Start where you actually are

This site is written for very different readers at once. Each door below leads into the same database from a different angle — nothing is dumbed down, and nothing assumes a biology degree.

Explore gene editing

Seven ways scientists change genetic material. Each page opens with a plain-language explanation, then goes as deep as you want.

All technologies →

Diseases being targeted

Each disease page states plainly whether gene editing is an approved treatment, in trials, or still only a laboratory idea.

All diseases →

Treatments

Named medicines, with regulatory status stated on every record.

Approved gene-editing medicines in the Atlas: Casgevy (exagamglogene autotemcel) · Lyfgenia (lovotibeglogene autotemcel) · Zynteglo (betibeglogene autotemcel)

All treatments →

Clinical trials

Where the evidence actually gets made.

4Recruiting
2Active, not recruiting
7Completed

Search the trial database →

Companies to know

Who is building what, and how far along each programme is.

All companies →

Scientists who changed the field

What each person actually contributed — attribution in this field is contested, and we say where.

All scientists →

Latest gene-editing news

Real articles from named publishers. Every headline links to the original — we never rewrite or republish them.

All news →
Pioneering Study of Alpha-Gal Syndrome Launched at Martha’s Vineyard Hospital Martha’s Vineyard Hospital launches a two-year study tracking up to 300 residents to understand who develops alpha-gal syndrome after lone star tick… GEN — Genetic Engineering News Research 8h ago Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg After a “comprehensive evaluation,” Bristol Myers Squibb has pulled out of its partnership with Cellares and the cell therapy manufacturer will… Endpoints News Treatments 9h ago Male Sex Hormones Suppress Lung Allergies by Acting on Neurons in Mice A study in mice found that male sex hormones can suppress allergic responses by promoting sympathetic nerve connections and norepinephrine release in the… GEN — Genetic Engineering News Research 1d ago Regenxbio hit with another clinical hold for Hunter syndrome gene therapy Regenxbio said it no longer expects to file for FDA approval of its Hunter syndrome gene therapy in the near future after the program was slapped with its… Endpoints News FDA 1d ago News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026 AstraZeneca, Ionis, Cytokinetics, Novartis and CRISPR Therapeutics, among others, will get a sense of the market potential of their heart drugs when data… Endpoints News Companies 1d ago STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more President Trump’s pledge to make pricey weight loss drugs widely available for low-income Americans through Medicaid is not panning out STAT Agriculture 1d ago STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged. STAT FDA 1d ago A CRISPR-based ‘dam-break drainage’ sensing architecture for rapid, affordable and ultrasensitive pathogen detection Nature Genetics Research 3d ago

CRISPR explained

Start at the very beginning. No biology background needed.

Start learning →

Gene editing by the numbers

Live counts from the Atlas database — these are the number of records we hold, not an estimate of the size of the field.

0Clinical trials trackedAtlas records
0Approved gene-editing therapiesFDA and/or EMA authorised
0Diseases coveredAtlas records
0CompaniesAtlas records
0ScientistsAtlas records
0GenesAtlas records
0TechnologiesAtlas records
0Connections between recordsKnowledge-graph edges

Counts refresh on every page load. “Approved” means a national medicines regulator has authorised at least one product; it does not mean the therapy is available or suitable for any particular person.

Before you read further The CRISPR Atlas is an educational reference. It does not provide medical advice, and information about an experimental therapy is never evidence that the therapy is safe or effective. Clinical-trial and regulatory status change frequently. If a decision about your own health or a family member's is involved, speak to a qualified healthcare professional. Read the full disclaimers →